Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FKBP prolyl isomerase 1A pseudogene 1 is formally listed as a pseudogene, meaning it is a non-coding genomic region with high sequence similarity to the protein-coding gene FKBP1A (FKBP12). Pseudogenes are generally viewed as transcriptionally inactive, but some are known to produce non-coding RNAs that regulate gene expression in other contexts. FKBP1AP1 is not implicated in canonical protein function, receptor action, or drug binding, and is not considered a receptor, enzyme, transporter, or direct disease biomarker. The true drug target in the FKBP family is FKBP1A (FKBP12), which binds immunosuppressive drugs like tacrolimus; FKBP1AP1 does not share this property and is included in molecular family lists only as a genomic annotation. FKBP1AP1 is NOT FKBP1A (FKBP12). FKBP1A is a protein-coding gene and bona fide therapeutic target for immunosuppressants, whereas FKBP1AP1 is a non-functional pseudogene. Most structured information relevant to drug development and biological function for FKBP proteins applies only to FKBP1A, not to FKBP1AP1.
None for drugs targeting this molecule; mechanisms described for FKBP1A (FKBP12), not this pseudogene
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FKBP prolyl isomerase 1A pseudogene 1 (FKBP1AP1).